Lee S. Rosen, MD

Lee S. Rosen, MD

Visiting Professor, Department of Medicine, Hematology/Oncology
Co-Director, UCLA Santa Monica Hematology Oncology at 2020
Director, Phase I Drug Development Program

Languages

English, Hebrew, Spanish, French

Specialty

Hematology, Medical Oncology

Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica

Education

Fellowship

Hematology/Oncology, UCLA School of Medicine, 1993 - 1996

Internship

Internal Medicine, UCLA School of Medicine, 1990 - 1991

Degrees

MD, Baylor College of Medicine, 1990
MPP, Public Policy, Harvard University, JFK School of Government, 1986

Residency

Internal Medicine, UCLA School of Medicine, 1991 - 1993

Board Certifications

Medical Oncology, American Board of Internal Medicine, 2010
Hematology, American Board of Internal Medicine, 1998
Internal Medicine, American Board of Internal Medicine, 1993

Contact Information

Clinical Interests

Advanced Malignancies, Cancers of Digestive Tract, Colorectal, Colon, Rectum, Anus, Esophageal Cancer, Gastric Cancer, Gastrointestinal Malignancies, General Oncology, Hepatobiliary Cancers, Liver Cancer, Pancreatic Cancer, Phase I Clinical Trials, Unknown Primary

Scientific Interests

Dr. Lee Rosen's research focuses on the development of new cancer therapies, particularly those with novel mechanisms of action. He is the principal investigator of more than 200 phase I clinical trials dating back to 1996, including some of the first involving anti-angiogenesis therapies. Collaborating with research efforts globally, Rosen is most interested in pharmacodynamic markers of safety and efficacy and in establishing new methods for the design and conduct of cancer clinical trials.

Highlighted Publications

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer. Clin Cancer Res. 2012 Sep 1;18(17):4820-9. Epub 2012 Jul 5.

Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res. 2012 Jun 15;18(12):3414-27. Epub 2012 Apr 17.

Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res. 2011 Dec 15;17(24):7754-64. Epub 2011 Oct 5.

Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009 Nov 15;15(22):7045-52. Epub 2009 Nov 10.

Rosen LS, Bilchik AJ, Beart RW Jr, Benson AB 3rd, Chang KJ, Compton CC, Grothey A, Haller DG, Ko CY, Lynch PM, Nelson H, Stamos MJ, Turner RR, Willett CG. New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6853s-6s.

In the News

View more articles